References of "Ruggeri, A"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOutcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, eurocord and EBMT collaborative analysis.
Ustun, C.; Giannotti, F.; Zhang, M.-J. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2017)

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FLT3+ acute myeloid leukemia (AML ... [more ▼]

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FLT3+ acute myeloid leukemia (AML) that has poor prognosis due to high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126), (HR 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically not significant 3-year LFS: 39% (95% CI 30-47) after UCB, 43% (95% CI 30-54) after sibling, and 50% (95% CI 40-60) after URD. Chronic GVHD rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2. UCB is a suitable option for adults with FLT3+AML in the absence of an HLA-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common thus allowing HCT in CR1 when outcomes are best.Leukemia accepted article preview online, 25 January 2017. doi:10.1038/leu.2017.42. [less ▲]

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailMethods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications
Baron, Frédéric ULg; Ruggeri, A.; Nagler, A.

in Expert Review of Hematology (2016), 21

More than 40,000 unrelated cord blood transplantations (UCBT) have been performed worldwide as treatment for patients with malignant or non-malignant life threatening hematologic disorders. However, low ... [more ▼]

More than 40,000 unrelated cord blood transplantations (UCBT) have been performed worldwide as treatment for patients with malignant or non-malignant life threatening hematologic disorders. However, low absolute numbers of hematopoietic stem and progenitor cells (HSPCs) within a single cord blood unit has remained a limiting factor for this transplantation modality, particularly in adult recipients. Further, because UCB contains low numbers of mostly naïve T cells, immune recovery after UCBT is slow predisposing patients to severe infections. Other causes of UCBT failure has included graft-versus-host disease (GVHD), and relapse of the underlying disease. In this article, we first review the current landscape of cord blood engineering aimed at improving engraftment. This includes approaches of UCB-HSPCs expansion and methods aimed at improving UCB-HSCPs homing. We then discuss recent approaches of cord blood engineering developed to prevent infection (generation of multivirus-specific cytotoxic T cells (VSTs) from UCB), relapse (transduction of UCB-T cells with tumor-specific chimeric receptor antigens (CARs)) and GVHD (expansion of regulatory T cells from UCB). Although many of these techniques of UCB engineering remain currently technically challenging and expensive, they are likely to revolutionize the field of UCBT in the next decades. [less ▲]

Detailed reference viewed: 68 (2 ULg)
Full Text
Peer Reviewed
See detailModification of standard ISHAGE methodology for CD34+ cells count on thawed Cord Blood Units: results from a multi-center Eurocord/Netcord study
Saccardi, RICCARDO; Azqueta, C; Ballerini, C et al

in Bone Marrow Transplantation (2015), 50

Detailed reference viewed: 69 (4 ULg)
Full Text
Peer Reviewed
See detailEffect of volume reduction of cord blood units before storage on transplantation outcomes: a retrospective analysis of Eurocord-EBMT and Netcord
SACCARDI, R; Tucunduva, L; Ruggeri, A et al

in Bone Marrow Transplantation (2013, April 01), 48

In this Registry study, manipulation of the CBUs aimed at volume reduction was not shown to infl uence the clinical outcome, indicating a satisfactory validation of the associated technologies across the ... [more ▼]

In this Registry study, manipulation of the CBUs aimed at volume reduction was not shown to infl uence the clinical outcome, indicating a satisfactory validation of the associated technologies across the banks. Cells viability assessment methodology varied among banks. Further eff orts to standardize the quality controls before CBU release are needed. [less ▲]

Detailed reference viewed: 36 (3 ULg)
Full Text
Peer Reviewed
See detailEffect of HLA-matching recipients to donor non-inherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy
Rocha, V; Spellman, S; Zhang, MJ et al

in Biology of Blood & Marrow Transplantation (2012)

Detailed reference viewed: 30 (5 ULg)
Peer Reviewed
See detailEvidence for basement membranes in rat tail tendon sheaths.
Guizzardi, S.; Foidart, Jean-Michel ULg; Leonardi, L. et al

in Basic and Applied Histochemistry (1987), 31(2), 177-81

The presence of anti-laminin antibodies and a basement membrane-like thin electrondense lamina has been demonstrated in the peritendineum of the rat tail tendon by indirect immunofluorescence and electron ... [more ▼]

The presence of anti-laminin antibodies and a basement membrane-like thin electrondense lamina has been demonstrated in the peritendineum of the rat tail tendon by indirect immunofluorescence and electron microscopy. [less ▲]

Detailed reference viewed: 9 (0 ULg)